Analytical Methods - USP's Future Expectations
Recommendation

Thursday, 3 September 2026 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
The Pharmacopoeial Forum 39(5) contains an interesting article from the USP Validation and Verification experts group about USP's future requirements on the development and validation of analytical methods.
The article is entitled "Lifecycle Management of Analytical Procedures: Method Development, Procedure Performance Qualification, and Procedure Performance Verification".
In this article, the USP experts group discusses how the modern concept of a lifecycle model (according to the ICH guidelines Q8, Q9, and Q10) can be transferred to analytical procedures. The experts group suggests that the traditional approach to validation, transfer and verification should be integrated into the new "lifecycle process" for the analytical procedure.
Concretely, they propose that the requirements for the measurement of critical quality attributes should be established in the "Analytical Target Profile".
In alignment with the process validation approach, three stages are proposed:
- Procedure Design (development and understanding)
- Procedure Performance Qualification
- Continued Procedure Performance Qualification
The article also describes possible approaches for changes and the related activities. At the end of the article, a summary table presents the new "Lifecycle Approach" against the current approach and lists all the advantages of the new approach.
You can find all information on the USP website of the Pharmacopeial Forum (PF).
PS: Dr Joachim Ermer - member of the USP experts group - will present USP's new approaches at the ECA Education Course HPLC in Analytical GMP Laboratories.
Source: USP
Related GMP News
01.07.2026Several FDA Warning Letters and Untitled Letters on Asbestos Testing of Talc in OTC Drug Products
24.06.2026Analytical Quality Group Developments January through April 2026
17.06.2026BioPhorum Publishes a Roadmap for QC Sample Test Execution
03.06.2026EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
03.06.2026FDA Warning Letter: Missing Method Validation - From a QC Topic to a Market-Access Problem
28.05.2026WHO Working Document on Bioequivalence open for Public Consultation


